AlphaQuest LLC Sells 12,031 Shares of DaVita Inc. $DVA

AlphaQuest LLC decreased its position in DaVita Inc. (NYSE:DVA) by 92.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 945 shares of the company’s stock after selling 12,031 shares during the quarter. AlphaQuest LLC’s holdings in DaVita were worth $126,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. KBC Group NV raised its holdings in DaVita by 38.7% in the 2nd quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after acquiring an additional 104,554 shares during the period. Nordea Investment Management AB grew its position in shares of DaVita by 1.8% in the third quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after purchasing an additional 5,193 shares during the last quarter. Man Group plc increased its stake in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC grew its holdings in DaVita by 49.1% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock valued at $36,730,000 after buying an additional 84,859 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on DVA. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Barclays boosted their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Truist Financial set a $158.00 price target on shares of DaVita in a report on Thursday, February 5th. TD Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Finally, UBS Group boosted their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $160.50.

DaVita Stock Up 3.9%

Shares of NYSE DVA opened at $149.84 on Friday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $178.38. The firm’s 50-day simple moving average is $117.07 and its 200 day simple moving average is $125.00. The company has a market cap of $10.58 billion, a price-to-earnings ratio of 15.12, a price-to-earnings-growth ratio of 0.50 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the firm posted $2.24 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.